SCHEMBL2174524

SCHEMBL2174524

CN(C(=O)O)c1cccc(-c2ccc(C=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
HSD17B2 P37059 5/20 0.47
HSD17B1 P14061 4/20 0.47
DRD1 P21728 1/20 0.46
CYP2A6 P11509 1/20 0.41
CYP2A13 Q16696 1/20 0.41
FFAR1 O14842 1/20 0.40
ERN1 O75460 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
PNPLA2 Q96AD5 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
BCHE P06276 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PTGS2 P35354 1/20 0.37
UNG P13051 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216636 0.81 BRD4 (0.40) TRIM24TRIM33HSD17B2HSD17B1ALDH1A1
SCHEMBL27618417 0.81 BRD4 (0.53) TRIM24TRIM33HSD17B2HSD17B1DRD1
SCHEMBL946362 0.78 CYP2A6 (0.59) CYP2A6CYP2A13ALDH1A1
SCHEMBL23912565 0.78 DRD1 (0.44) TRIM24TRIM33HSD17B2HSD17B1DRD1
SCHEMBL28764495 0.78 PTGS2 (0.50) HSD17B2HSD17B1PTGS2
SCHEMBL5386767 0.77 GSK3B (0.59)
SCHEMBL23904955 0.76 GRIA2 (0.47) HSD17B2HSD17B1DRD1CYP2A6CYP2A13
SCHEMBL3948563 0.75 AOC3 (0.57) TRIM24TRIM33HSD17B2HSD17B1BCHE
SCHEMBL23912566 0.75 DRD1 (0.41) TRIM24TRIM33HSD17B2HSD17B1DRD1
SCHEMBL23576817 0.74 ALDH1A1 (0.60) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973063-B2 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-07-05 US disclosed
EP-1742608-B1 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR(GAMMA) TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2010-02-24 EP disclosed
US-20100035988-A1 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-02-11 US disclosed
US-7626054-B2 Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-01 US disclosed
US-7294639-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-11-13 US disclosed
US-20070112070-A1 Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-17 US disclosed
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-02-22 US disclosed
US-7122564-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-17 US disclosed
EP-1458697-B1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RES & DEV (FR) 2006-09-06 EP disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
EP-1458697-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS Galderma Research & Development, S.N.C. (FR) 2004-09-22 EP disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed
WO-2003055867-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112070-A1 Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA TRIM24 3733/4885TRIM33 4222/4885HSD17B2 580/4885
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors PPARG, PPARA, PPARD TRIM24 3463/4885TRIM33 3928/4885HSD17B2 278/4885
US-20100035988-A1 Methods for activating PPAR gamma-type receptors PPARG, PPARA, PPARD TRIM24 3867/4885TRIM33 3687/4885HSD17B2 404/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD TRIM24 3463/4885TRIM33 3928/4885HSD17B2 278/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD TRIM24 3271/4885TRIM33 3962/4885HSD17B2 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.